Acquired Dermal Melanocytic Hyperpigmentation
Acquired dermal melanocytic hyperpigmentation (ADMH) is a unifying term for a spectrum of dermal pigmentary disorders characterized by insidious-onset grey-to-brown macules and patches caused by melanin deposition in the dermis, without a clinically apparent inflammatory phase 1.
Clinical Definition and Spectrum
ADMH serves as an umbrella concept that consolidates previously distinct entities including:
- Lichen planus pigmentosus
- Erythema dyschromicum perstans (ashy dermatosis)
- Riehl's melanosis/pigmented cosmetic dermatitis
- Idiopathic macular eruptive pigmentation
These conditions were traditionally regarded as separate diseases but share substantial overlapping clinical, dermoscopic, and histopathological features, leading to adoption of ADMH as the preferred unifying terminology 1, 2, 3.
Key Clinical Features
Presentation:
- Small to large pigmented macules or patches
- Grey-to-brown coloration (distinguishing feature from epidermal pigmentation)
- Insidious onset without preceding clinically significant inflammation
- Most commonly affects the face, though extrafacial involvement (neck, chest, upper extremities, back) can occur 1, 4
- More prevalent in females and darker skin types 5
Pathophysiology: The condition results from dermal melanin deposition, predominantly attributed to:
- Interface dermatitis with pigment incontinence
- UV exposure
- Hormonal influences
- Contact sensitization (in some cases) 5, 2
Diagnostic Approach
Histopathology reveals three recognized patterns 6:
- Type 1 (40%): Basal cell degeneration with moderate to dense inflammation
- Type 2 (40%): Significant pigment incontinence with sparse inflammation, no basal cell degeneration
- Type 3 (20%): Sparse inflammation without basal cell degeneration or significant pigment incontinence
These patterns may represent different stages of the same disease process rather than distinct entities, though this requires confirmation through prospective studies 6.
Dermoscopy shows characteristic features across the ADMH spectrum and is useful for both diagnosis and monitoring therapeutic response 2, 7.
Clinical Significance
- Quality of Life Impact: ADMH can be esthetically displeasing and significantly impair patient quality of life 5, 3
- Chronic Nature: The condition follows a variable, protracted disease course requiring long-term management 5, 3
- Diagnostic Challenge: Lack of clinically apparent inflammatory phase and overlapping features make diagnosis challenging without histopathological confirmation 3
Recent Classification Proposal
A contemporary classification approach divides ADMH into:
- Cases with contact sensitization
- Cases without contact sensitization
This distinction may have therapeutic implications 2.
Important Clinical Pitfall
Do not confuse ADMH with acquired dermal melanocytosis (ADM), which specifically refers to ectopic dermal melanocytes (like Mongolian spots presenting after infancy), typically appearing as blue-grey patches most commonly on the face 8, 9. While both involve dermal pigmentation, ADM represents melanocytes themselves in the dermis, whereas ADMH represents melanin deposition from interface dermatitis.
The adoption of ADMH as a unifying term facilitates research, therapeutic trials, and clinical management of these challenging pigmentary disorders that were previously fragmented across multiple diagnostic categories 3.